Sutro Biopharma, Inc.
STRO
$0.8578
$0.01021.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 63.75M | 17.40M | 14.81M | 8.52M | 25.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.75M | 17.40M | 14.81M | 8.52M | 25.71M |
| Cost of Revenue | 38.33M | 2.28M | -168.50M | 62.11M | 62.02M |
| Gross Profit | 25.42M | 15.12M | 183.31M | -53.59M | -36.31M |
| SG&A Expenses | 10.34M | 13.27M | 9.03M | 14.33M | 12.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.67M | 64.87M | 80.07M | 76.44M | 74.39M |
| Operating Income | 15.08M | -47.47M | -65.26M | -67.92M | -48.69M |
| Income Before Tax | -11.52M | -75.97M | -70.09M | -48.79M | -48.01M |
| Income Tax Expenses | -18.00K | -- | 2.36M | -- | 8.00K |
| Earnings from Continuing Operations | -11.50M | -75.97M | -72.44M | -48.79M | -48.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.50M | -75.97M | -72.44M | -48.79M | -48.02M |
| EBIT | 15.08M | -47.47M | -65.26M | -67.92M | -48.69M |
| EBITDA | 16.98M | -45.57M | -63.39M | -66.12M | -46.90M |
| EPS Basic | -0.14 | -0.91 | -0.88 | -0.59 | -0.59 |
| Normalized Basic EPS | 0.05 | -0.41 | -0.53 | -0.55 | -0.41 |
| EPS Diluted | -0.14 | -0.91 | -0.88 | -0.59 | -0.59 |
| Normalized Diluted EPS | 0.05 | -0.41 | -0.53 | -0.55 | -0.41 |
| Average Basic Shares Outstanding | 84.58M | 83.11M | 82.51M | 82.04M | 81.22M |
| Average Diluted Shares Outstanding | 84.58M | 83.11M | 82.51M | 82.04M | 81.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |